GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (STU:RFS) » Definitions » Cyclically Adjusted PB Ratio

Resverlogix (STU:RFS) Cyclically Adjusted PB Ratio : (As of Jan. 31, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Resverlogix Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Resverlogix Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Resverlogix's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Cyclically Adjusted PB Ratio Chart

Resverlogix Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Resverlogix Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Resverlogix's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Resverlogix's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resverlogix's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Resverlogix's Cyclically Adjusted PB Ratio falls into.



Resverlogix Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Resverlogix's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Resverlogix's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.267/127.2847*127.2847
=-0.267

Current CPI (Sep. 2024) = 127.2847.

Resverlogix Quarterly Data

Book Value per Share CPI Adj_Book
201410 -0.494 99.473 -0.632
201501 -0.553 98.209 -0.717
201504 -0.791 99.710 -1.010
201507 -0.302 100.579 -0.382
201510 -0.326 100.500 -0.413
201601 -0.412 100.184 -0.523
201604 -0.473 101.370 -0.594
201607 -0.539 101.844 -0.674
201610 -0.669 102.002 -0.835
201701 -0.806 102.318 -1.003
201704 -0.897 103.029 -1.108
201707 -0.867 103.029 -1.071
201710 -0.882 103.424 -1.085
201801 -0.368 104.056 -0.450
201804 -0.385 105.320 -0.465
201807 -0.641 106.110 -0.769
201810 -0.719 105.952 -0.864
201901 -0.702 105.557 -0.846
201904 -0.923 107.453 -1.093
201907 -0.848 108.243 -0.997
201910 -0.354 107.927 -0.417
202001 -0.320 108.085 -0.377
202004 -0.279 107.216 -0.331
202007 -0.270 108.401 -0.317
202010 -0.192 108.638 -0.225
202103 -0.140 110.298 -0.162
202106 -0.133 111.720 -0.152
202109 -0.152 112.905 -0.171
202112 -0.218 113.774 -0.244
202203 -0.222 117.646 -0.240
202206 -0.226 120.806 -0.238
202209 -0.230 120.648 -0.243
202212 -0.211 120.964 -0.222
202303 0.000 122.702 0.000
202306 -0.229 124.203 -0.235
202309 -0.246 125.230 -0.250
202312 -0.251 125.072 -0.255
202403 -0.245 126.258 -0.247
202406 -0.261 127.522 -0.261
202409 -0.267 127.285 -0.267

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Resverlogix  (STU:RFS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Resverlogix Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Resverlogix's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Resverlogix Business Description

Industry
Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Resverlogix Headlines

No Headlines